glp-1 class action in dallas At least 3,000 patients have filed lawsuits against the companies behind GLP -1 weight loss drugs, alleging severe health risks, including blindness. NewsNation's Brooke Shafer has the story on "Morning America." GLP-1 receptor agonists and cardiovascular

Recent Mergers & Acquisitions (M & A) 2025-2026: Mar 2026: BioMarin Pharmaceutical agreed to acquire rare disease biotech Amicus Therapeutics for $4.8B, strengthening metabolic & rare disease franchise overlap with diabetes-associated disorders Mar 2026: Sanofi entered $2.2B acquisition deal for Dynavax Technologies to expand vaccine and immunometabolic pipeline supporting diabetes-comorbidity therapeutics Jan 2026: Eli Lilly and Company announced acquisition of Ventyx Biosciences for $1.2B, expanding cardiometabolic and diabetes-related pipeline into immunology-linked therapies 2026 (closed/announced): Merck & Co

This decision is intentional to ensure that the product is properly stored and handled before reaching consumers

Starting weight and body composition People with higher starting weights generally lose more total pounds but a similar or slightly lower percentage of body weight compared to people starting at lower weights

Medicare announced in late 2025 it will begin covering anti-obesity medications a game-changer for providers serving seniors